PDF icon Download PDF
Exp Clin Endocrinol Diabetes 2010; 118(10): 735-740
DOI: 10.1055/s-0030-1261912
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

L-Carnitine Supplementation and Adipokines in Patients with End-Stage Renal Disease on Regular Hemodialysis

B. Csiky1 , 2 , Z. Nyul3 , G. Tóth3 , I. Wittmann2 , B. Melegh4 , M. Rauh5 , W. Rascher5 , E. Sulyok6
  • 1FMC Dialysis Center Pécs, Faculty of Medicine, University of Pécs, Pécs, Hungary
  • 2Nephrological Center and 2nd Department of Medicine, Faculty of Medicine, University of Pécs, Pécs, Hungary
  • 3Department of Pediatrics, Faculty of Medicine, University of Pécs, Pécs, Hungary
  • 4Department of Medical Genetics and Child Development, Faculty of Medicine, University of Pécs, Pécs, Hungary
  • 5Klinik für Kinder und Jugendliche, University of Erlangen-Nürnberg, Nürnberg, Germany
  • 6Institute of Public Health and Health Promotion and Family Care, Faculty of Health Sciences, University of Pécs, Pécs, Hungary
Further Information

Publication History

received 23.11.2009 first decision 10.03.2010

accepted 31.05.2010

Publication Date:
23 July 2010 (online)

Also available ateRef
   Permissions and Reprints
Preview

Abstract

Chronic hemodialysis (HD) patients frequently encounter carnitine depletion, elevated adipose tissue-derived hormones/cytokines, that may contribute to accelerated arteriosclerosis. 10 non-diabetic HD patients were studied over 28 weeks. In the 12 weeks treatment period 1 g l-carnitine was given iv after each HD session. Measurements of plasma free- and acylcarnitines, insulin, leptin, adiponectin, resistin and ghrelin were performed at baseline, at weeks 2, 4, 8, 12 (treatment period) and at weeks 24–28 (post-treatment period). L-carnitine supplementation resulted in progressive increase of free- and acylcarnitine levels. Plasma levels of insulin, resistin, leptin and ghrelin remained at the already elevated baseline values. L-carnitine therapy induced a significant increase in plasma adiponectin from 20.2±12.7 μg/ml (baseline) to 32.7±20.2 μg/ml in week 2 (p<0.05) and 35.4±19.6 μg/ml in week 12 (p<0.03), which remained unchanged in the post-carnitine period. Plasma insulin levels correlated positively with leptin (r=0.525, p<0.0001) and resistin (r=0.284, p<0.005); adiponectin levels correlated inversely with leptin (r=−0.255, p<0.02) and resistin (r=−0.213, p<0.04) irrespective of carnitine status. Plasma levels of adipokines and related hormones are greatly elevated in patients on regular HD. L-carnitine administration further augmented the plasma levels of protective adiponectin, therefore it may have a role in preventing cardiovascular complications of uremia.

Key words

adipokines - carnitine - end-stage renal disease - hemodialysis

References

  • 1 Antuna-Puente B, Feve B, Fellahi S. et al . Adipokines: the missing link between insulin resistance and obesity.  Diabetes Metabolism. 2008;  34 2-11
    Search in Google Scholar
  • 2 Axelsson J, Bergsten A, Qureshi AR. et al . Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance.  Kidney Int. 2006;  69 596-604
    Search in Google Scholar
  • 3 Axelsson J, Stenvinkel P. Role of fat mass and adipokines in chronic kidney disease.  Curr Opin Nephrol Hypertens. 2008;  17 25-31
    Search in Google Scholar
  • 4 Beddhu S, Kimmel PL, Ramkumar N. et al . Associations of metabolic syndrome with inflammation in CKD: results from the Third National Health and Nutrition Examination Survey (NHANES III).  Am J Kidney Dis. 2005;  46 577-586
    Search in Google Scholar
  • 5 Belay B, Esteban-Cruciani N, Walsh CA. et al . The use of levo-carnitine in children with renal disease: a review and a call for future studies.  Pediatr Nephrol. 2006;  21 308-317
    Search in Google Scholar
  • 6 Bellinghieri G, Santoro D, Calvani M. et al . Carnitine and hemodialysis.  Am J Kidney Dis. 2003;  41 (Suppl. 1) S116-S122
    Search in Google Scholar
  • 7 Calò La, Pagnine E, Davis PA. et al . Antioxidant effect of l-carnitine and its short chain esters. Revelance for the protection from oxidative stress related cardiovascular damage.  Int J Cardiol. 2006;  107 54-60
    Search in Google Scholar
  • 8 Capaldo B, Napoli R, DiBonito P. et al . Carnitine improves peripheral glucose disposal in non-insulin-dependent diabetic patients.  Diabetes Res Clin Pract. 1991;  14 191-195
    Search in Google Scholar
  • 9 Costacou T, Orchard TJ. Adiponectin: good, bad, or just plain ugly?.  Kidney Int. 2008;  74 549-551
    Search in Google Scholar
  • 10 Daschner M, Tonshoff B, Blum WF. et al . Inappropriate elevation of serum leptin levels in children with chronic renal failure.  J Am Soc Nephrol. 1998;  9 1074-1079
    Search in Google Scholar
  • 11 Duranay M, Akay H, Yilmaz FM. et al . Effects of l-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients.  Nephrol Dial Transplant. 2006;  21 3211-3214
    Search in Google Scholar
  • 12 Eknoyan G, Latos DL, Lindberg J. Practice recommendations for the use of l-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference.  Am J Kidney Dis. 2003;  41 868-876
    Search in Google Scholar
  • 13 Ellis BA, Poynten A, Lowy AJ. et al . Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle.  Am J Physiol Endocrinol Metab. 2000;  279 E554-E560
    Search in Google Scholar
  • 14 Evans A. Dialysis-related carnitine disorder and levocarnitine pharmacology.  Am J Kidney Dis. 2003;  41 (Suppl. 4) S13-S26
    Search in Google Scholar
  • 15 Gunal AI, Celiker H, Donder E. et al . The effect of l-carnitine on insulin resistance in hemodialysed patients with chronic renal failure.  J Nephrol. 1999;  12 38-40
    Search in Google Scholar
  • 16 Hoppel C. The role of carnitine in normal and altered fatty acid metabolism.  Am J Kidney Dis. 2003;  41 (Suppl. 4) S4-S12
    Search in Google Scholar
  • 17 Hurot J-M, Cucherate M, Haugh M. et al . Effects of l-cartinine supplementation in maintenance hemodialysis patients: A systematic review.  J Am Soc Nephrol. 2002;  13 708-714
    Search in Google Scholar
  • 18 Iglesias P, Diez JJ, Fernandez-Reyes MJ. et al . Serum ghrelin concentrations in patients with chronic renal failure undergoing dialysis.  Clin Endocrinol. 2006;  64 68-73
    Search in Google Scholar
  • 19 Jorsal A, Tarnow L, Frystyk J. et al . Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy.  Kidney Int. 2008;  74 649-654
    Search in Google Scholar
  • 20 Kalantar-Zadeh K, Block G, McAlister CJ. et al . Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients.  Am J Clin Nutr. 2004;  80 299-307
    Search in Google Scholar
  • 21 Kalantar-Zadeh K, Kopple JD. Obesity paradox in patients on maintenance dialysis.  Contrib Nephrol. 2006;  151 57-69
    Search in Google Scholar
  • 22 Karakitsos D, De Groot E, Patrianakos AP. et al . Adiponectin and cardiovascular remodeling in end-stage renal disease and co-morbid diabetes mellitus.  Am J Nephrol. 2006;  26 340-347
    Search in Google Scholar
  • 23 Nüsken K-D, Kratzsch J, Wienholz V. et al . Circulating resistin concentrations in children depend on renal function.  Nephrol Dial Transplant. 2006;  21 107-112
    Search in Google Scholar
  • 24 Pecoits-Filho R, Lindholm B, Stenvinkel P. End-stage renal disease: a state of chronic inflammation and hyperleptinemia.  Eur J Clin Invest. 2003;  33 527-528
    Search in Google Scholar
  • 25 Rajala MW, Obici S, Scherer PE. et al . Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production.  J Clin Invest. 2003;  111 225-230
    Search in Google Scholar
  • 26 Shen YY, Charlesworth JA, Kelly JJ. et al . Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease.  Nephrol Dial Transplant. 2007;  22 171-178
    Search in Google Scholar
  • 27 Schreiber B. Levocarnitine and dialysis: A review.  Nutr Clin Pract. 2005;  20 218-243
    Search in Google Scholar
  • 28 Scholze A, Rattensperger D, Zidek W. et al . Low serum leptin concentration predicts mortality in patients with chronic kidney disease stage 5 on hemodialysis therapy.  Obesity. 2007;  15 1617-1622
    Search in Google Scholar
  • 29 Talián GL, Komlósi K, Decsi T. et al . Determination of carnitine ester patterns during the second half of pregnancy, at delivery, and in neonatal cord blood by tandem mass spectrometry: complex and dynamic involvement of carnitine in the intermediary metabolism.  Pediatr Res. 2007;  62 88-92
    Search in Google Scholar
  • 30 Van Gaal LF, Mertens IL, De Block CE. Mechanism linking obesity with cardiovascular disease.  Nature. 2006;  444 875-880
    Search in Google Scholar
  • 31 Vernez L, Dickenmann M, Steiger J. et al . Effect of L-carnitine on the kinetics of carnitine, acylcarnitines and butyrobetaine in long-term haemodialysis.  Nephrol Dial Transplant. 2006;  21 450-458
    Search in Google Scholar
  • 32 Yamauchi T, Kamon J, Minokoshi Y. et al . Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activating protein kinase.  Nat Med. 2002;  8 1288-1295
    Search in Google Scholar

Correspondence

B. CsikyMD, PhD 

FMC Dialysis Center Pécs

2nd Department of Medicine

and Nephrological Center

Faculty of Medicine

University of Pécs

Pacsirta u. l. H-7624 Pécs

Hungary

Phone: +36/72/536 067

Fax: +36/72/536 070

Email: botond.csiky@gmail.com